Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
Open Access
- 1 April 2020
- journal article
- research article
- Published by Wiley in Cancer Cell
- Vol. 108 (2), 350-357
- https://doi.org/10.1002/cpt.1835
Abstract
Assessments of clinical evidence vary between regulators and health technology assessment bodies, but precise differences remain unclear. To compare uncertainties raised on the clinical evidence of approved drugs, we analyzed assessments of regulators and health technology assessment (HTA) bodies in the United States and Europe. We found that US and European regulators report uncertainties related to safety for almost all drugs (85–94%), whereas HTA bodies reported these less (53–59%). By contrast, HTA bodies raised uncertainties related to effects against relevant comparators for almost all drugs (88–100%), whereas this was infrequently addressed by regulators (12–32%). Regulators as well as HTA bodies reported uncertainties related to the patient population for 60–95% of drugs. The patterns of regulator‐HTA misalignment were comparable between the United States and Europe. Our results indicate that increased coordination between these complementary organizations is necessary to facilitate the collection of necessary evidence in an efficient and timely manner.Keywords
This publication has 35 references indexed in Scilit:
- The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvementsClinical Trials, 2018
- Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other MedicinesHealth Affairs, 2018
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug AdministrationJAMA, 2017
- Approvals in 2016: questioning the clinical benefit of anticancer therapiesNature Reviews Clinical Oncology, 2017
- Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?Annals Of Oncology, 2016
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalJAMA Internal Medicine, 2015
- From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patientsCancer Cell, 2014
- Accelerated Access to Innovative Medicines for Patients in NeedCancer Cell, 2014
- New FDA Breakthrough-Drug Category — Implications for PatientsNew England Journal of Medicine, 2014
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012JAMA, 2014